Login with your work email address to view charts. No credit card required.
| Art Unit: | 1618 — Drug, bio-affecting and body treating compositions |
|---|---|
| Group: | 1610 — Pharmaceutical and Agricultural Compositions; Plant Growth Regulating Compositions: Bio-affecting, Body Treating, Drug Delivery, Steroids, Herbicides, Pesticides, Cosmetics, and Drugs; In vivo Diagnostic Agents |
| Classes: |
424 — Drug, bio-affecting and body treating compositions 600 — Surgery 506 — Combinatorial chemistry technology: method, library, apparatus 604 — Surgery 514 — Drug, bio-affecting and body treating compositions |
| Phone: | (571) 272-9928 |
| Email: | leah.schlientz@uspto.gov |
| Location: | VA 22314 |
| Title: | Pat Examnr Org Chem |
| Service: | 20 years |
| Grade: | GS-13 |
| 3-Year Grant rate: | 49% over 214 cases |
|---|---|
| Difficulty: | Very Hard |
| Difficulty Percentile: | 81st
|
With Examiner Schlientz, you have a 49% chance of getting an issued patent by 3 years after the first office action. Examiner Schlientz is a very hard examiner and in the 81st percentile across all examiners (with 100th percentile most difficult).
Below is the grant rate timeline for Examiner Schlientz, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.
Examiner Schlientz's grant rate is lower than that of Art Unit 1618 and lower than that of the USPTO.
| Average Office Actions Per Grant | |
|---|---|
| Examiner Schlientz | 2.2 |
| Art Unit 1618 | 2.0 |
Subscribe to Premium Examiner Statistics for unlimited access to our examiner statistics.
Subscribe to Premium Examiner Statistics for unlimited access to our examiner statistics.
Subscribe to Premium Examiner Statistics for unlimited access to our examiner statistics.
Subscribe to Premium Examiner Statistics for unlimited access to our examiner statistics.
Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.